This project is Memorial Sloan-Kettering Cancer Center's (MSKCC) application to become a Network Lead Academic Participating Site for the NCI National Clinical Trials Network (NCTN). The MSKCC project aims are scientific leadership in development of NCTN trials, scientific leadership in the activities of the NCTN and NCI Scientific Steering Committees, patient accrual on NCTN Trials, and mentoring junior investigators in clinical trial research. MSKCC has the resources to both bring strong scientifically driven studies to the network and to participate in studies brought forth by other network participants. MSKCC has a multidisciplinary team of investigators committed to translational research, a large patient population amenable to participation in clinical trials, an superb infrastructure to support such trials. MSKCC has full membership in Alliance for Clinical Trials in Oncology, GOG and RTOG and is an affiliate member of ECOG. MSKCC has strong leadership and expertise in advanced imaging and participates in ACRIN studies on a case-by-case basis. The multiple Principal Investigators in this Network Lead Academic Site U10 are experienced leaders in the Network Groups with a track record of meeting these scientific, accrual and mentoring aims. As a large center focused solely on cancer, we have a particular expertise and commitment to the NCTN mission of evaluating rare tumors.

Public Health Relevance

As a Network Lead Academic Participating Site MSKCC will be a leader in the scientific development, conduct and accrual of NCTN clinical trials with the overall goal of developing new treatments for cancer patients. This will be achieved through definitive, randomized, clinical treatment and advanced imaging trials across a broad range of diseases and diverse patient populations, as well as development efforts preliminary to those trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA180791-02S1
Application #
9198616
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-15
Project End
2019-02-28
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
2
Fiscal Year
2016
Total Cost
$400,000
Indirect Cost
$162,117
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Choueiri, Toni K; Hessel, Colin; Halabi, Susan et al. (2018) Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eu Eur J Cancer 103:287
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Choueiri, Toni K; Hessel, Colin; Halabi, Susan et al. (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer 94:115-125
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021

Showing the most recent 10 out of 77 publications